Experimental therapies using nanoparticles: nanomaterials in triple-negative breast cancer (TNBC) treatment

Abstract Triple-negative breast cancer (TNBC) accounts for approx. 10–20% of breast cancer diagnoses worldwide. Triple-negative breast cancer cells have no estrogen nor progesterone receptors and lack overexpression of human epidermal growth factor receptor. As no hormone therapy can be implemented, chemotherapy remains the main weapon. Nowadays, widely available chemo regimens for TNBC treatment can consist of anthracyclines, taxanes, antimetabolites, or platinums, but all of the aforementioned are highly toxic to the bone marrow, liver, kidneys, and nervous system. Targeted treatment using nanotechnology seems to be a ray of hope in impeding this morbid disease.